Detalles de la búsqueda
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048557
2.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36528035
3.
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.
Lancet Oncol
; 24(10): 1119-1133, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37717583
4.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34774221
5.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Haematologica
; 105(7): 1937-1947, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31582542
6.
Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.
Biol Blood Marrow Transplant
; 24(7): 1372-1378, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29408334
7.
Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience.
Biol Blood Marrow Transplant
; 20(5): 717-23, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24525280
8.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Blood
; 120(1): 9-19, 2012 Jul 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-22498745
9.
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Blood
; 118(22): 5759-66, 2011 Nov 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-21951682
10.
Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy.
Haematologica
; 103(10): e469-e472, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29700168
11.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
EClinicalMedicine
; 60: 102017, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37396807
12.
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Blood
; 116(23): 4745-53, 2010 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-20807892
13.
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
Blood
; 115(10): 1873-9, 2010 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-19965659
14.
Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status.
Front Immunol
; 13: 1073227, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36605214
15.
Diagnosis of maternal Hodgkin lymphoma following abnormal findings at noninvasive prenatal screening test (NIPT): Report of two cases.
Clin Case Rep
; 9(3): 1066-1071, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33768784
16.
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.
Pharmaceuticals (Basel)
; 14(1)2020 Dec 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-33383757
17.
Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
J Med Case Rep
; 14(1): 75, 2020 Jun 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32564775
18.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol
; 7(6): e456-e468, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32359506
19.
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.
J Hematol Oncol
; 12(1): 4, 2019 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30626425
20.
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
Lancet
; 367(9513): 825-31, 2006 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-16530576